burimamide burimamide burimamide is an antagonist at the h2 and h3 histamine receptors. it is largely inactive as an h2 antagonist at physiological ph, but its h3 affinity is 100x higher. it is a thiourea derivative. burimamide names iupac name 1--3-methylthiourea identifiers cas number 34970-69-9 y 3d model (jsmol) interactive image chembl chembl12160 y chemspider 2297780 y kegg c07448 y pubchem cid 3032915 unii tn5a4od2tv y comptox dashboard (epa) dtxsid00188519 inchi inchi=1s/c9h16n4s/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7h,2-5h2,1h3,(h,11,13)(h2,10,12,14) ykey: hxrbavxgyzused-uhfffaoysa-n yinchi=1/c9h16n4s/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7h,2-5h2,1h3,(h,11,13)(h2,10,12,14)key: hxrbavxgyzused-uhfffaoyaj smiles cnc(=s)nccccc1ccn1 properties chemical formula c9h16n4s molar mass 212.32 g/mol except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). y verify (what is yn ?) infobox references burimamide was first developed by scientists at smith, kline & french (sk&f; now glaxosmithkline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers. the discovery of burimamide ultimately led to the development of cimetidine (tagamet).